Immunex Message Board - Msg: 17025888

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LemurHouse who wrote (652)	2/6/2002 11:42:06 PM
From: mopgcw	Read Replies (1) of 656

NZ's Genesis, Immunex Sign 3-Year Collaboration Pact DOW JONES NEWSWIRES WELLINGTON -- New Zealand biotechnology concern Genesis Research & Development Corp. (A.GEN) and U.S.-based Immunex Corp. (IMNX) have signed a three-year agreement covering joint research and commercial development of pharmaceuticals. Genesis Chief Executive Jim Watson said Thursday that the partnership allows the two companies to collaborate on specific drugs that are candidates for commercial development. It also gives Genesis an opportunity to work with a recognized expert in the drug development area, he said. Genesis currently has two drugs that are candidates for commercial development - a therapeutic vaccine for psoriasis and a therapeutic vaccine for asthmaa.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next